In This Article:
Merit Medical Systems MMSI released 12-month efficacy results for its WRAPSODY Cell-Impermeable Endoprosthesis (“CIE”), demonstrating strong performance in vascular access maintenance. Designed to enhance long-term outcomes for patients with end-stage renal disease, WRAPSODY CIE leverages advanced technology to improve vessel patency and reduce complications.
This milestone underscores Merit Medical's dedication to innovation in interventional medicine. With promising clinical data, WRAPSODY CIE reinforces its potential as a reliable solution for patients requiring vascular access, strengthening the company’s position in the medical device industry.
Likely Trend of the MMSI Stock Following the News
Following the announcement, shares of the company closed flat at $104.74 yesterday. In the past six months, MMSI’s shares have gained 6.7% compared with the industry’s 4.4% growth. The S&P 500 improved 1.1% in the same time frame.
Positive clinical results for WRAPSODY CIE can boost the performance of the MMSI stock in the long run by increasing demand for the product, driving higher sales and strengthening the company’s reputation in the medical device industry. As hospitals and healthcare providers adopt this advanced technology, revenue growth could follow, attracting more investors. Additionally, strong efficacy data can lead to regulatory approvals in more regions, expanding market reach.
Meanwhile, MMSI currently has a market capitalization of $6.16 billion. The company delivered an earnings surprise of 12.1% in the last reported quarter.
Image Source: Zacks Investment Research
More on MMSI’s WRAPSODY CIE Study Results
MMSI has announced that the six-month results from the randomized arm of the WRAPSODY Arteriovenous Access Efficacy (“WAVE”) trial are scheduled for publication in the April issue of Kidney International. The WAVE trial, a multicenter international study, evaluates the safety and efficacy of WRAPSODY CIE in maintaining vascular access for hemodialysis patients. Given the critical nature of vascular access in hemodialysis treatment, WRAPSODY CIE aims to provide a long-term solution for patients experiencing stenosis in their venous outflow circuits.
The trial’s randomized arm involved 245 patients undergoing hemodialysis, comparing WRAPSODY CIE to standard percutaneous transluminal angioplasty (PTA). Treatment efficacy was measured based on the proportion of patients who maintained primary patency at the target lesion and access circuit, without requiring reintervention. At six months, WRAPSODY CIE demonstrated superior performance, with target lesion primary patency at 89.8% versus 62.8% for PTA , and access circuit primary patency at 72.6% versus 57.9% for PTA. These results indicated a significant advantage in maintaining vascular access and reducing the need for repeated interventions.